Mycoplasmosis is one of the most common causes of inflammatory diseases of the genitourinary system. The danger of this infectious agent is that, being sexually transmitted, it does not manifest itself for a long time and does not cause any distinct symptoms of the disease. But with hypothermia, nervous or physical overexertion, during pregnancy, mycoplasmosis enters an acute stage and, without proper timely treatment, becomes the cause of severe inflammatory processes, often leading to infertility, both in men and women, and also to a complicated course of pregnancy.
What is the danger of mycoplasmosis and the reasons for its activation
There are many types of mycoplasmas, but those that can cause inflammation of the organs of the genitourinary system and are transmitted through sexual contact are especially dangerous for humans. Mycoplasmosis affects both men and women. Inflammatory processes that are caused by mycoplasma can lead to both male and female infertility, since, among other organs, the uterus and its appendages in women and the prostate gland in men are affected.
Mycoplasmosis and its complications are especially dangerous for pregnant women, as they can cause miscarriages, early rupture of amniotic fluid, development of pathologies of the eyes, lungs, and genitourinary system in newborns.
According to the observations of specialists, during the visit of patients suffering from chronic diseases - such as pyelonephritis, inflammation of the bladder, urethritis, prostatitis, endometritis and others - in almost 60% of patients, mycoplasmosis is detected, which provoked the inflammatory process. Very often, mycoplasmosis does not manifest itself for a long time, about 15% of the examined healthy patients have mycoplasmas that do not cause them discomfort. Stress, hypothermia, abortion, exacerbation of other gynecological or urological diseases can become an impetus for the transition of mycoplasmosis to an acute form.
Methods of infection and characteristic symptoms of mycoplasmosis
It is possible to become infected with mycoplasmosis practically only through sexual contact, the infection is transmitted extremely rarely by household means. The symptomatology of the disease is very similar to infectious lesions experienced by the organs of the genitourinary system from other pathogens (for example, chlamydia or Trichomonas). The latent period of the development of the disease averages about two weeks, although in a weakened organism, mycoplasmosis can develop within three days.
Often, mycoplasmosis occurs without any symptoms at all, or patients do not pay much attention to intermittent discharge from the urethra or from the vagina (in women), which can be either transparent or white or yellowish in color. Among the complaints that patients still usually present are the following:
- pain during sexual contact,
- drawing pains in the lower abdomen, in the lumbar region,
- burning when urinating,
- itching and inflammation in the area of the urethral opening.
If treatment is not started in the early stages of mycoplasmosis, then there is a rather severe pain in the perineum and in the rectum. A complication of mycoplasmosis often becomes an inflammatory process in the bladder, chronic prostatitis in men and inflammation of the uterine appendages in women. Often, patients go to the doctor with just such an inflammatory process, which greatly complicates the diagnosis of the disease and leads to a more complex and lengthy treatment process.
The correct approach to the treatment of mycoplasmosis and the prognosis of the disease
Mycoplasmosis responds well to special treatment, especially in the initial or earliest stages of the disease. Antibacterial drugs become the basis of therapy, but they need to be selected individually, based on the results of laboratory diagnostics and taking into account the sensitivity of the pathogen to a particular type of antibiotic.
Antibacterial therapy for mycoplasmosis is recommended to be combined with immunomodulators, if necessary, local symptomatic treatment is prescribed. Therapy should be administered, if possible, to both sexual partners at the same time to eliminate the risk of reinfection.
Share:
Add a comment